ArticleAntimicrobial agents and chemotherapy2013
Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile.
Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Efficacy and safety of rifaximin in preventing hepatic encephalopathy: A systematic review and meta-analysis.PloS one · 2025Pooled it
- Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis.Medicine · 2021Pooled it
- Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection withGut · 2019Trial
- Characterization of Food ChainMicroorganisms · 2023Article
- Non-Toxin-BasedPathogens (Basel, Switzerland) · 2023Article
- Improving Management of Portal Hypertension: The Potential Benefit of Non-Etiological Therapies in Cirrhosis.Journal of clinical medicine · 2023Review
- Rifamycin antibiotics and the mechanisms of their failure.The Journal of antibiotics · 2021Review
- Antimicrobial resistance in chronic liver disease.Hepatology international · 2020Review
- Italian nationwide survey of pharmacologic treatments in diverticular disease: Results from the REMAD registry.United European gastroenterology journal · 2019Article
- [Treatment of acute and recurrent Clostridium difficile infections : What is new?]Der Internist · 2018Review
- Novel Antimicrobials for the Treatment ofFrontiers in medicine · 2018Review
- Rifamycin Resistance in Clostridium difficile Is Generally Associated with a Low Fitness Burden.Antimicrobial agents and chemotherapy · 2016Article
- Use of rifaximin in gastrointestinal and liver diseases.World journal of gastroenterology · 2016Review
- Rifamycins, Alone and in Combination.Cold Spring Harbor perspectives in medicine · 2016Review
- Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection.Therapeutic advances in infectious disease · 2016Review
- Using a Novel Lysin To Help Control Clostridium difficile Infections.Antimicrobial agents and chemotherapy · 2015Article
- Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.Current topics in medicinal chemistry · 2014Review
- The potential for emerging therapeutic options for Clostridium difficile infection.Gut microbes · 2014Review
- Molecular epidemiology and antimicrobial resistance in Clostridioides difficile strains isolated from children and adolescents in a tertiary referral pediatric hospital in Fortaleza, Brazil.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesArticle
- Conventional and alternative treatment approaches forInternational journal of health sciencesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
The relationship between rifamycin drug use and the development of resistant strains of Clostridium difficile was studied at a large university hospital in Houston, TX, between May 2007 and September 2011. In 49 of 283 (17.3%) patients with C. difficile infection (CDI), a rifamycin-resistant strain of C. difficile was identified that compares to a rate of 8% using the same definitions in 2006-2007 (P = 0.59). The 49 patients infected by a resistant organism were matched by date of admission to 98 control patients with CDI from whom a rifamycin-susceptible C. difficile strain was isolated. Cases and controls did not differ according to demographic and clinical characteristics and showed similar but low rates of prior rifamycin use. Similar rates of rifamycin resistance were seen in cases of hospital-acquired CDI (38/112 [34%]) versus community-acquired CDI (7/20 [35%]). At a university hospital in which rifaximin was commonly used, infection by rifamycin-resistant strains of C. difficile was not shown to relate to prior use of a rifamycin drug or to acquiring the infection in the hospital, although the rate of overall resistance appeared to be rising.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.